Diabetes Complication Control in Community Clinics (D4C) Trial (D4C)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- Xiamen Diabetes Institute, Xiamen University
-
-
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men or women aged ≥50 years who received primary care from the participating community clinics
- Uncontrolled diabetes (HbA1C ≥7% or ≥7.5% if with clinical CVD) with at least one additional CVD risk factor (SBP ≥140 and/or DBP ≥90 mm Hg and/or LDL-cholesterol ≥100 mg/dL) or clinical ASCVD (acute coronary syndromes, ischemic stroke, transient ischemic attack, or peripheral artery disease)
Exclusion Criteria:
- Patients with NYHA class II-IV heart failure, or receiving hemodialysis, or with contraindications to metformin or statin treatments
- Women who are pregnant or plan to become pregnant
- Patients who cannot be followed for 36 months (due to a health situation or migration)
- Patients who are unwilling or unable to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Protocol-based Integrated Care
The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by care team (trained primary care physicians, health managers, and nurses supported by diabetes specialists) and assisted by a clinical decision support systems.
|
The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
|
|
Active Comparator: Enhanced Control
A usual team-based care delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
|
The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HbA1C, SBP, and LDL between intervention and control groups, simultaneously modeled using a scaled marginal model which allows estimation of a single overall treatment effect and combined control rate of HbA1c, SBP, and LDL
Time Frame: 18 months
|
For patients younger than 65 years, HbA1c ≤7.0% or ≤8.0% in those with complications; for patients 65 years or older, HbA1c ≤7.5% or HbA1c ≤8.5% in those with complications; LDL-cholesterol <100 mg/dL; and blood pressure <140/90 mm Hg
|
18 months
|
|
Incidence of composite major cardiovascular disease events
Time Frame: Three years
|
Non-fatal stroke, non-fatal myocardial infarction, hospitalized heart failure, and CVD mortality
|
Three years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1C
Time Frame: 18 months
|
Net change in HbA1c or proportion of controlled HbA1c
|
18 months
|
|
SBP
Time Frame: 18 months
|
Net change in SBP or proportion of controlled BP
|
18 months
|
|
LDL-cholesterol
Time Frame: 18 months
|
Net change in LDL or controlled LDL
|
18 months
|
|
CVD risk score
Time Frame: 18 months
|
10-year risk of CVD using ACC/AHA Risk Scores
|
18 months
|
|
Health-related quality of life: 12-item Short-Form Health Survey
Time Frame: Three years
|
Health-related quality of life by the 12-item Short-Form Health Survey
|
Three years
|
|
Cost-effectiveness
Time Frame: Three years
|
Incremental Cost-Effectiveness Ratio
|
Three years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Jiang He, MD, PhD, Tulane University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 889920-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.